Navigation Links
InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
Date:3/6/2009

- Company Receives Allowance of Patent Claims in the U.S. and in India -

- InNexus Biotechnology CEO Highlighted in Nature Biotechnology -

BRITISH COLUMBIA, Canada, March 6 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces that it has received a notice of allowance on patent claims in the United States (Serial No. 11/119,404) and a patent grant in India (National Phase Application No. 2424/CHENP/2005) further expanding its protection of InNexus' DXL(TM) technology.

Speaking on today's announcement, InNexus Chairman and CEO, Jeff Morhet said, "DXL(TM) antibodies that penetrate directly into cells, is an exciting achievement for InNexus and our industry. As we've continued to expand our patent portfolio and discover new technologies to develop products, the team has aggressively pursued patent protection for our novel inventions. Patents are the currency of our industry and a driver for enhanced value for our shareholders and potential use of these cell penetrating DXL(TM) antibodies represents another frontier for the use of antibodies for therapeutic and diagnostic applications."

Dr. Thomas Kindt, Chief Scientific Officer of InNexus said, "The claims in these patents are directed toward the addition of membrane transport sequences to DXL antibodies, which facilitate penetration of DXL(TM) antibodies into cancer cells. The ability to direct our DXL(TM) antibodies to intracellular targets by the addition of a membrane transport sequence, imparts great therapeutic potential in a number of applications. The patents and applications also include coverage for new molecules and products of InNexus. We like to say We Build Better Antibodies and today, we demonstrated that once again."

InNexus also announced that Jeff Morhet, Chairman and CEO, was recently highlighted and quoted in an article titled "JAMA study casts cloud over biologic safety" in the January 2009 issue of Nature Biotechnology. A copy of the article can be downloaded at: http://www.nature.com/nbt/journal/v27/n1/pdf/nbt0109-11.pdf. Nature Biotechnology is a widely read academic journal published by Nature Publishing Group, a division of Macmillan Publishers Ltd., covering the science and business of biotechnology.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product
2. InNexus Completes Previously Announced Private Placement
3. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
4. InNexus Biotechnology Receives Patent Grants in Europe
5. InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
6. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
7. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
8. InNexus Biotechnology Strengthens Patent Team With New Leadership
9. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
10. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
11. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... (AI) and leading supplier of Semantic Graph Database technology, today announced the availability ... release of Cloudera Enterprise through the Cloudera Certified Technology Program (CCPT). ...
(Date:2/8/2016)... 2016 --> ... "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces ... trachomatis (CT) test to be launched on the Company,s io® ... the CT test is now cleared for sale within the ... The launch of the io® CT test signals a new ...
(Date:2/5/2016)...  In the pharmaceutical industry the medical affairs function ... activities including the identification and engagement of key thought ... high in the oncology therapeutic area where most treating ... Role of Medical Affairs in Oncology Launch Excellence ." ... find better ways to utilize medical affairs to develop ...
(Date:2/4/2016)... ... February 04, 2016 , ... Morf Media Inc ... an interactive FDA compliance training course, Writing Effective SOPs ... accredited interactive course on Morf Playbook—now conveniently available on smartphones and PCs--provides step ...
Breaking Biology Technology:
(Date:2/3/2016)... Sweden , February 4, 2016 --> ... amounted to SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter ... profit amounted to SEK 517.6 M (loss: 30.0). Earnings per ... operating activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared ...
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
Breaking Biology News(10 mins):